Innovating CGT Breakthroughs, Gathering at East Taihu: CGT Industrialization Summit and Puxin Biologics' First Anniversary Celebration

Gu HongjianAddress

Member of the Party Working Committee and Deputy Director of the Administrative Committee of Suzhou Wuzhong Economic and Technological Development Zone

Paradise Suzhou, Most Beautiful Wuzhong. This summit has invited numerous experts and leading figures from the cell and gene therapy industry to participate. It serves not only as a significant opportunity for the Wuzhong Economic and Technological Development Zone to strengthen friendships with old and new partners and jointly pursue development, but also as the most important annual exchange event in the industry.

Zhu YiAddress by the Ph.D.

CEO of Puxin Bio

The past year was one of arduous struggle, as well as breakthrough and transformation. With the CGT field continuously evolving, PuXin Bio is leveraging this momentum to build a unique service model based on its technical expertise, contributing to the industrialization of CGT. We hope that more drugs will emerge in the future market, helping us stay free from disease.

Composing a New Chapter in CGT,

Write about CDMO sentiment.

Reflecting on the Past, Looking to the Future.

Two Strategic Agreements,

Celebrating the First Anniversary of the Puxin Biology Brand Launch.

Li Cha, COO of PuXin Bio (left), and Zhang Xian, Head of Business Development at XianBo Bio (right)

PuXin Biology CEO Zhu Yi (left) and HaiJinge Medicine CSO Sun Liying (right)

Gu Hongjian (4th from right), Member of the Party Working Committee and Deputy Director of the Administrative Committee of Suzhou Wuzhong Economic and Technological Development Zone; Zhang Dan (4th from left), Foreign Academician of the Russian Academy of Engineering, Chief Scientific Officer at Shenzhen Xingwan Company, and Co-founder & CSO of Kunling Medicine; Li Hongjian (3rd from right), Chairman of Puxin Biology; Shi Zhiwei (3rd from left), Director of the Biopharmaceutical Division at Suzhou Bureau of Industry and Information Technology; Yang Wei (2nd from right), Chairman and General Manager of Lion Medicine; Cheng Zengjiang (2nd from left), Founder of Tongxieyi Forum; Zhu Yi (1st from right), CEO of Puxin Biology; and Li Cha (1st from left), COO of Puxin Biology.

Eighteen Years of Shared Vision,

Accumulate Strength, Forge Ahead Together.

The CGT Industry Is Booming,

Gathering Again, the Sages Leave Their Names in History.

Group Photo with Some Executive Directors of the Tongxieyi CGT Club

During the conference, the Tongxieyi CGT Club elected a new chairperson and nine members of the standing council, and deliberated to formulate the Initiative for the Development of China’s Cell and Gene Therapy Industry.

The Tongxieyi CGT Club aims to unite visionary and mission-driven talents in China specializing in the research and development (R&D), clinical application, and industrialization of cell and gene therapies. Together, we explore the scientific essence of innovation in cell and gene therapy R&D, promote the scientifically grounded formulation of regulatory guidelines, exchange and share R&D experiences and insights, cultivate and develop more industry R&D professionals, and foster the healthy development of novel cell and gene therapy drug development in China.

Wei WenshengVideo Address by the Professor

Advisor, Tongxieyi CGT Club

Professor, School of Life Sciences, Peking University

In his opening remarks, Professor Wei stated, “No technology exists in isolation; it must be integrated into the industrial ecosystem to realize its true value, and cell and gene therapy (CGT) is no exception. I believe that the industry leaders present here have a deeper appreciation of this point. In my view, this is precisely the rationale behind the establishment of the CGT Club by Tongxieyi: to create an interactive platform for exchange, thereby fostering industry clustering and ecosystem development.”

Fan XiaohuDr.'s Video Address

Executive Director of the Tongxieyi CGT Club

Former Co-Founder and CSO of Nanjing Legend Biotech

“The development of China’s CGT sector has been remarkably rapid, yielding a series of significant advancements and achievements. I firmly believe that China will emerge as the global leader in the field of cell and gene therapy (CGT). Currently, we have already surpassed Europe and the United States in many specialized subsectors, and this trend is poised to expand further. Over the next two to three decades, CGT will become the mainstream direction in biopharmaceuticals. Let us strive together toward this future.”

He said, “Having reached the age of twenty and undergone the capping ceremony, I grew ever more admiring of the ways of the sages and worthies.”

A Sincere Heart, a Regret-Free Life in Medicine.

CGT, innovative drugs... The road ahead is long and arduous.

Professor Ma Jun

Advisor, Tongxieyi CGT Club

Director of the Harbin Institute of Hematology and Oncology, Chairman of the CSCO Board of Supervisors

Since the FDA approved the CD20 monoclonal antibody rituximab in November 1997 for the treatment of B-cell lymphoma, and subsequently approved the small-molecule targeted therapy imatinib mesylate in May 2001 for the treatment of chronic myeloid leukemia, hematologic malignancies have entered a new era of molecular targeted therapy. Currently, small-molecule targeted drugs, monoclonal antibodies, bispecific antibodies, antibody-drug conjugates (ADCs), and CAR-T cell therapies are emerging in rapid succession for the treatment of hematologic malignancies, demonstrating encouraging efficacy and holding considerable promise for the future.

Wang LiqunPh.D.

Chairman of the Tongxieyi CGT Club

Founder, Chairman and CEO of Xingyiang Biotech

Limitations such as single targets or narrow indications, constraints in clinical application, and high costs leading to expensive pricing are all pain points associated with autologous cell therapy. Next-generation immune cell therapeutic products must feature universality, scalability for mass production, and efficacy against solid tumors. Cell therapy is currently a hot sector in innovative drug development, with enormous market potential. The race has only just begun; innovation and resilience are the two core elements of success.

Li JinsongAcademician

Advisor, Tongxieyi CGT Club

Researcher, CAS Center for Excellence in Molecular Cell Science

Applications of semi-cloning technology include rapid modeling of complex diseases, genetic screening during embryonic development, studies on the developmental regulation of genomic imprinting, and genome tagging initiatives. In summary, semi-cloning techniques, based on microinsemination and cloning, facilitate research in development and disease.

Zhang DanAcademician

Foreign Academician of the Russian Academy of Engineering, Chief Scientific Officer at Shenzhen Xingwan Company

Co-founder & CSO of Kunling Pharmaceuticals

Challenges in Clinical Trials of CGT Therapies Encompass Multiple Aspects. First, the uniqueness of each cell and gene therapy product and its corresponding clinical trial. Second, the complex logistics tracking and management required for cell and gene therapy products and patient cellular tissue samples during clinical trials. Third, the variability in patient responses to cell and gene therapies. Fourth, the specific regulations and approval processes for cell and gene therapies in different countries. Fifth, the qualification requirements for hospitals administering cell and gene therapies. The rapid development of CDMOs/CROs will facilitate the development of CGT therapies.

Moderated by Dr. Cheng Zengjiang, founder of the Tongxieyi Forum, leading figures from various innovative institutions presented their companies’ product portfolios and expressed their aspirations for future collaboration.

The sky is ablaze with rosy clouds, bathing heaven and earth in orange and gold.

How Can China's CGT Industry Achieve Sustained and Healthy Development?

Urgent need for industry self-discipline and care from the entire society.

Tongxieyi CGT Club,

Encourage win-win cooperation,

Advocating Positive Energy,

Shoulder the responsibility.

Proposal by the Tongxieyi CGT Club on the Development of China’s Cell and Gene Therapy Industry

Board Meeting Venue

Breaking free from a roundtable,

A long, straight table is set up.

The Clash Between Tradition and Modernity,

A Feast of the Classical and the Contemporary.

No need to drag Li Bai into a drunken stupor,

Can also sprinkle frost across the Nine Provinces,

Forging bonds across the four seas,

Together, let us compose a new chapter in CGT.

Amidst the clinking of wine cups and the shuffle of gaming chips, all the guests are in high spirits.

The moon hangs high among the branches, at its peak.

Innovative thoughts mingle with the chirping of cicadas and the croaking of frogs,

Riding the shimmering waves of East Taihu Lake,

Falling into the sun, moon, and stars.

This is the true essence of a free-spirited cocktail party,

This is the Tongxieyi Executive Lounge.

"Fellow Travelers,"

"Why Need We Have Met Before?"

When the cocktail party turns into a sing-along for guests,

The gathering of industry leaders has thus become the company’s annual conference.

Li Jinsong: Researcher at the CAS Center for Excellence in Molecular Cell Science, Academician of the Chinese Academy of Sciences

Ma Jun: Director of the Harbin Institute of Hematology and Oncology; Chairman of the Supervisory Board of CSCO

Zhang Dan: Foreign Member of the Russian Academy of Engineering, Chief Scientific Officer at Shenzhen Xingwan Company, Co-founder & CSO of Kunling Pharma

Wang Liqun: Founder, Chairman and CEO of Xingyiang Bio

Li Hongjian: Chairman of Pu Xin Bio

Zhu Yi: CEO of Pu Xin Bio

Wei Dong: CEO of Edigen

Zhou Guoying: Chairman and CEO of Innovent Biotherapeutics

Zhang Yu: CSO, Vcanbio

Cheng Zengjiang: Chairman of Kebeyuan Bio

Sun Liying: CSO, Haijinge Pharmaceutical

Zhang Xian: Head of Business Development at Xianbo Bio

Yang Wei: Chairman and General Manager of Laine Pharmaceuticals

Li Cha: Chief Operating Officer of PuXin Bio

Chen Qi: General Manager, WuXi Biologics China

Chen Xu: Chairman and Founder of Yikesai

Cheng Jinsheng: Vice President of Tofflon and General Manager of the Life Sciences Business Unit

Cui Wenhao: CEO of Youjia Bio

Fan Jing: Founder of Huode Biotech

Hu Yang: CEO of MicroLight Genomics

Kong Lingjie: CSO, Porton Biologics

Li Linhong: CEO of Celsior

Li Xiang: Founder, CEO, and CSO of Shize Biotech

Li Yiping: CEO of JW Therapeutics

Li Yongfeng: Chief Marketing Officer, PuXin Bio

Lin Qing: CEO of Lingyi Bio

Liu Bin: COO, Shenyan Bio

Liu Haiyang: CEO of BioRayce

Liu Wei: Chairman of Huakan Biotechnology

Liu Yarong: CEO of GravelBio

Lu Lulu: CEO of Heyuan Bio

Shang Yuanfang: Founder and CEO of CytoBridge Bio

Shang Xiaoyun: CEO of Maoxing Bio

Su Zhenbo: Founder of Tiankeya

Sun Lele: Founder and CEO of Xuzhenda

Tian Xiaopeng: Associate Chief Physician, Department of Hematology, The First Affiliated Hospital of Soochow University

Wang Wen: CEO and CMO of Reindeer Health

Wang Gang: CEO of Kega Biologics

Wang Jun: Chairman and General Manager of XcessBio

Wang Quanjun: Chief Scientist at Saifu Pharma

Wang Tongsheng: Head of Production, Zilong Bio

Bei Peipei: Head of Quality, Zilong Bio

Wang Zifeng: Chairman of Shengyan Biotech

Wu Lanlin: Co-founder and CEO of Kemeixin

Wu Qiong: Chief Commercial Officer and SVP of JW Therapeutics

Xiao Shan: Deputy General Manager of Naikang Bio

Xu Xianbin: Deputy General Manager of PuXin Bio

Xu Yuanyuan: Founder and Chairman of Kray Gene

Yang Huanfeng: CEO of Yuanqi Bio

Yang Lin: Founder and Chairman of Bioray Pharmaceuticals

Yang Wei: Chairman and General Manager of Ryan Pharma

Yao Shuyuan: CEO of Annuolinglu Pharmaceuticals

Yuan Jijun: EVP, Abogen Biosciences

Zhang Jinhua: Founder and Chairman of Xunlu Medical

Zhang Ting: Founder and CEO of Regend Therapeutics

Zhang Yan: Co-Founder of MegaRobo

Zhang Ying: Co-founder of Zhongsheng Suyuan

Zheng Weiyi: Chairman of Nuobiao Biology

Zhu Fangfang: Founder of Xueji Bio

Zhu Min: Senior Vice President of Jianxin Yuanli

Zuo Chijian: Co-founder and CSO of CareMed

Puxin Biotechnology is headquartered in Wuzhong District, Suzhou City, on the beautiful shores of Lake Taihu, with its Suzhou headquarters (10,000 m²)² GMP Facility), Shenzhen Base (8,000 m²²(GMP-compliant facilities under construction), initially establishing a nationwide production base network; the North Carolina facility in the United States is also under construction, advancing global expansion simultaneously. We have established a nucleic acid platform dedicated to cell therapies, a suspension serum-free virus production platform, and a fully closed cell process development platform, creating an express lane for cell therapy products from discovery to delivery. These platforms have supported multiple partners in successfully incubating various CAR-T, TCR-T, and stem cell therapies. Puxin Biologics is committed to helping more projects reach their next milestones earlier and faster, bringing more cell therapies to market to benefit more patients, and writing a new chapter in life with cell therapies.